BBX high mobility group box domain containingGenealiases: ARTC1 · HBP2 · HSPC339 · MDS001
Q-omics provides the consensus-scored BBX profile across patient tissues and cancer cell-line models. BBX expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BBX is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, BBX RNA expression shows 20,864 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where BBX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBX survival associations across molecular data types. BBX RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBX RNA expression–survival associations across cancer types. High BBX expression shows unfavorable associations in CESC, ACC and UCEC, but favorable associations in KIRC, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BBX RNA expression.
This table summarizes BBX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BBX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBX shows lower tumor expression in THCA, KIRC and UCEC and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher BBX RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with BBX in patient tissues and cancer cell lines. In patient samples, BBX shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BBX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
